大师级运动员心血管异常处理的临床共识声明
本共识由欧洲预防心脏病学会与美国心脏病学会联合制定,针对大师级运动员常见心血管异常(房性心律失常、冠脉粥样硬化、主动脉扩张、心肌纤维化等)的诊疗挑战提出专家意见。现有指南多基于有症状的久坐患者,不完全适用于高强度训练的运动员,该共识旨在为此类人群的诊断评估、管理和预后提供更新建议。
要点
- 大师级运动员心血管异常(如房颤、冠脉病变)患病率可能高于低活动量同龄人,需主动筛查。
- 解读消费者可穿戴设备数据,注意症状表现与久坐患者存在差异。
- 启动药物治疗时充分考虑运动员的抵触心理及对运动表现的影响。
核心结论
- 大师级运动员较同龄低活动量者,房性心律失常、冠脉粥样硬化、主动脉扩张及心肌纤维化的患病率可能更高。
研究设计与样本
- 制定机构为欧洲预防心脏病学会与美国心脏病学会,采用临床共识声明的形式,基于专家经验整合现有证据。
主要发现
- 现有心血管指南多基于有症状的久坐患者数据建立,难以直接外推至高度训练的运动员个体。
- 大师级运动员的症状表现、对药物启动的抵触心理及可穿戴设备数据的涌现,均增加了临床评估复杂性。
关键数值与推荐
- 对房颤、缓慢性心律失常、室性心律失常、冠脉粥样硬化、主动脉扩张、心肌纤维化及运动诱发型心律失常心肌病,提出了诊断评估与管理的专家路径。
临床怎么用
- 临床评估时应整合来自消费者可穿戴设备的健康数据作为参考信息。
- 管理策略需个体化,权衡药物治疗对运动员运动表现及生活质量的影响。
局限性
- 缺乏基于运动员群体的临床结局研究及专用随机对照试验。
- 需要建立不同人群的国际注册登记并进行纵向随访,以明确心脏异常的自然史。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Exercise training improves cardiovascular health and reduces the risk for future cardiovascular events and mortality. However, emerging evidence suggests that Masters athletes may have a higher prevalence of cardiovascular abnormalities, such as atrial arrhythmias, coronary atherosclerosis, aortic dilatation, and myocardial fibrosis, compared to their less active peers. The clinical management of Masters athletes may be challenging as available guidelines for such conditions are generally based on data derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals. Other unique challenges in the clinical assessment of Masters athletes include differences in symptomatic presentations compared to sedentary individuals, potential resistance to the initiation of pharmacologic treatment, and the increasing availability of consumer wearable health data that may provide relevant information on their cardiovascular health status. The purpose of this joint EAPC/ESC and ACC Clinical Consensus Statement is to provide an in-depth update on the current state of knowledge on abnormal cardiovascular findings in Masters athletes. We present an expert-based approach on the diagnostic assessment, management, and prognosis of (i) atrial fibrillation, (ii) bradyarrhythmias, (iii) ventricular arrhythmias, (iv) coronary atherosclerosis, (v) aortic dilatation, (vi) myocardial fibrosis, and (vii) exercise-induced arrhythmogenic cardiomyopathy. Clinical challenges, areas of ongoing controversy, and uncertainty and the potential underlying mechanisms are discussed. We also present future perspectives and research directives to further refine current best practice strategies. This includes the need for clinical outcome studies, dedicated randomized controlled trials in athletes, and international registries with diverse populations and longitudinal follow-up to evaluate the natural history of cardiac abnormalities and facilitate development of evidence-based approaches in the clinical management of Masters athletes with cardiovascular abnormalities.
引用
- Eijsvogels, Kim, Aengevaeren, et al. Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology. Eur Heart J. 2026. PMID: 41947397. doi:10.1093/eurheartj/ehag040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。